Tautomycin and Enzalutamide Combination Yields Synergistic Effects on Castration-Resistant Prostate Cancer

The authors reported an approach for suppressing reactivated androgen receptor (AR) signaling in the castration-resistant prostate cancer (CRPC) stage. A combination of the tautomycin and enzalutamide synergistically inhibited cell proliferation and AR signaling in LNCaP and C4-2 cells, as well as in AR variant-positive 22RV1 cells.